Identification of a PCSK9-LDLR disruptor peptide with in vivo function

被引：32

作者：

Brousseau, Margaret E. ^{[1
]}

Clairmont, Kevin B. ^{[1
]}

Spraggon, Glen ^{[2
]}

Flyer, Alec N. ^{[1
]}

Golosov, Andrei A. ^{[1
]}

Grosche, Philipp ^{[3
]}

Amin, Jakal ^{[1
]}

Andre, Jerome ^{[3
]}

Burdick, Debra ^{[1
]}

Caplan, Shari ^{[1
]}

Chen, Guanjing ^{[1
]}

Chopra, Raj ^{[1
]}

Ames, Lisa ^{[1
]}

Dubiel, Diana ^{[1
]}

Fan, Li ^{[1
]}

Gattlen, Raphael ^{[3
]}

Kelly-Sullivan, Dawn ^{[1
]}

Koch, Alexander W. ^{[1
]}

Lewis, Ian ^{[3
]}

Li, Jingzhou ^{[1
]}

Liu, Eugene ^{[1
]}

Lubicka, Danuta ^{[1
]}

Marzinzik, Andreas ^{[3
]}

Nakajima, Katsumasa ^{[1
]}

Nettleton, David ^{[1
]}

Ottl, Johannes ^{[3
]}

Pan, Meihui ^{[1
]}

Patel, Tajesh ^{[1
]}

Perry, Lauren ^{[1
]}

Pickett, Stephanie ^{[3
]}

Poirier, Jennifer ^{[1
]}

Reid, Patrick C. ^{[4
]}

Pelle, Xavier ^{[3
]}

Seepersaud, Mohindra ^{[1
]}

Subramanian, Vanitha ^{[1
]}

Vera, Victoria ^{[1
]}

Xu, Mei ^{[1
]}

Yang, Lihua ^{[1
]}

Yang, Qing ^{[1
]}

Yu, Jinghua ^{[1
]}

Zhu, Guoming ^{[1
]}

Monovich, Lauren G. ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, 22 Windsor St & 181 Massachusetts Ave, Cambridge, MA 02139 USA

[2] Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA

[3] Novartis Inst BioMed Res, Fabrikstr 2,Novartis Campus, CH-4056 Basel, Switzerland

[4] PeptiDream Inc, Meguro Ku, KOL Bldg,Room 405,4-6-1 Komaba, Tokyo 1538904, Japan

来源：

CELL CHEMICAL BIOLOGY | 2022年 / 29卷 / 02期

关键词：

SMALL-MOLECULE INHIBITORS; FACTOR-LIKE REPEAT; CRYSTAL-STRUCTURE; ANNEXIN A2; PROTEIN; DESIGN; BINDING; ANTIBODIES; DISPLAY; SITE;

D O I：

10.1016/j.chembiol.2021.08.012

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma low-density lipoprotein cholesterol (LDL-C) levels by promoting hepatic LDL receptor (LDLR) degradation. Therapeutic antibodies that disrupt PCSK9-LDLR binding reduce LDL-C concentrations and cardiovascular disease risk. The epidermal growth factor precursor homology domain A (EGF-A) of the LDLR serves as a primary contact with PCSK9 via a flat interface, presenting a challenge for identifying small molecule PCSK9-LDLR disruptors. We employ an affinity-based screen of 10(13) in vitro-translated macrocyclic peptides to identify high-affinity PCSK9 ligands that utilize a unique, induced-fit pocket and partially disrupt the PCSK9-LDLR interaction. Structure-based design led to molecules with enhanced function and pharmacokinetic properties (e.g., (13)PCSK9i). In mice,(13)PCSK9i reduces plasma cholesterol levels and increases hepatic LDLR density in a dose-dependent manner. (13)PCSK9i functions by a unique, allosteric mechanism and is the smallest molecule identified to date with in vivo PCSK9-LDLR disruptor function.

引用

页码：249 / +

页数：16

共 50 条

[21] Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation
Abdelwahed, Khaldoun S.
Siddique, Abu Bakar
Ebrahim, Hassan Y.
Qusa, Mohammed H.
Mudhish, Ethar A.
Rad, Ashkan H.
Zerfaoui, Mourad
Abd Elmageed, Zakaria Y.
El Sayed, Khalid A.
MARINE DRUGS, 2023, 21 (04)
[22] On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects
Tavori, Hagai
Rashid, Shirya
Fazio, Sergio
ATHEROSCLEROSIS, 2015, 238 (02) : 264 - 270
[23] APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo
Fu, Ting
Guan, YangYang
Xu, Junjie
Wang, Yan
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2017, 1862 (09): : 883 - 889
[24] Small Molecule Inhibitors of the PCSK9•LDLR Interaction
Taechalertpaisarn, Jam
Zhao, Bosheng
Liang, Xiaowen
Burgess, Kevin
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2018, 140 (09) : 3242 - 3249
[25] PCSK9 Interaction with LDLR Interferes with Apoe Binding
Yamamoto, Taichi
Ryan, Robert O.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (11) : E205 - E205
[26] The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
Ataei, Sarina
Ganjali, Shiva
Banach, Maciej
Karimi, Ehsan
Sahebkar, Amirhossein
ARCHIVES OF MEDICAL SCIENCE, 2023, 19 (01) : 203 - 208
[27] Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells
Fasano, Tommaso
Sun, Xi-Ming
Patel, Dilipkumar D.
Soutar, Anne K.
ATHEROSCLEROSIS, 2009, 203 (01) : 166 - 171
[28] SOLUBLE LDLR ASSOCIATES WITH MULTIPLE LIPOPROTEIN PARAMETERS IN A CAUCASIAN POPULATION AND ITS ASSOCIATION WITH SERUM PCSK9 IS AFFECTED BY PCSK9 LOSS OF FUNCTION
Mayne, Janice
Tepliakova, Lioudmila
Seebun, Deeptee
Walker, Krystal
Mohottalage, Dhanuddara
Ning, Zhibin
Abujrad, Hussein
Mbikay, Majambu
Wassef, Hanny
Chretien, Michel
Ooi, Teik Chye
Figeys, Daniel
ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 9 - 9
[29] Improving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide
Zhang, Yuhui
Wang, Li
Tombling, Benjamin J.
Lammi, Carmen
Huang, Yen-Hua
Li, Yue
Bartolomei, Martina
Hong, Bin
Craik, David J.
Wang, Conan K.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2022, 42 (19485-19498) : 19485 - 19498
[30] Improving stability enhances in vivo efficacy of a PCSK9 inhibitory peptide
Zhang, Yuhui
Wang, Li
Tombling, Benjamin
Lammi, Carmen
Huang, Yen-Hua
Yue, Li
Bartolomei, Martina
Hong, Bin
Craik, David
Wang, Conan
JOURNAL OF PEPTIDE SCIENCE, 2024, 30

← 1 2 3 4 5 →